CoChat
Sign Up
Cited by 674Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerHeat shock proteins research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Open access
Shangary, Sanjeev, Qin, Dongguang, McEachern, Donna, Liu, Meilan, Miller, Rebecca S., Qiu, Su, Nikolovska-Coleska, Zaneta, Ding, Ke, Wang, Guoping, Chen, Jianyong, Bernard, Denzil, Zhang, Jian, Lu, Yipin, Gu, Qingyang, Shah, Rajal B., Pienta, Kenneth J., Ling, Xiaolan, Kang, Sanmao, Guo, Ming, Sun, Yi, Yang, Dajun, Wang, Shaomeng·2008·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.0708917105PMC PMC2268798
Open this paper in CoChat — free account

Abstract

We have designed MI-219 as a potent, highly selective and orally active small-molecule inhibitor of the MDM2–p53 interaction. MI-219 binds to human MDM2 with a K i value of 5 nM and is 10,000-fold selective for MDM2 over MDMX. It disrupts the MDM2–p53 interaction and activates the p53 pathway in cells with wild-type p53, which leads to induction of cell cycle arrest in all cells and selective apoptosis in tumor cells. MI-219 stimulates rapid but transient p53 activation in established tumor xenograft tissues, resulting in inhibition of cell proliferation, induction of apoptosis, and complete tumor growth inhibition. MI-219 activates p53 in normal tissues with minimal p53 accumulation and is not toxic to animals. MI-219 warrants clinical investigation as a new agent for cancer treatment.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.0708917105

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

  1. CG Maki, JM Huibregtse, PM Howley Cancer Res 56, 2649–2654 (1996).
  2. WS el-Deiry, JW Harper, PM O'Connor, VE Velculescu, CE Canman, J Jackman, JA Pietenpol, M Burrell, DE Hill, Y Wang, et al. Cancer Res 54, 1169–1174 (1994).

Cited by

Sorted by citations

Items 601–674 of 674

Related

See all

Metadata

Authors
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., Pienta, K. J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., & Wang, S.
Affiliations
  • University of Michigan (US)
  • *Comprehensive Cancer Center and Department of Internal Medicine and
  • Ascenta Therapeutics, Inc., Malvern, PA 19355
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
2008-03-11
Volume
105
Issue
10
Pages
3933-3938
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.0708917105
PMC
PMC2268798
OpenAlex
W1992947288
Cited by
660
References
42
Citations by year
2026: 9 · 2025: 9 · 2024: 16 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 35 · 2019: 34 · 2018: 29 · 2017: 28 · 2016: 42 · 2015: 43 · 2014: 65 · 2013: 45 · 2012: 67
FWCI
30.50
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Prostate Cancer Foundation (P30CA046592)
  • Leukemia and Lymphoma Society
  • National Institutes of Health
  • National Cancer Institute (R01CA121279, P50CA069568, P30CA046592)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
MDM2 inhibitors, p53 activation, p53-MDM2 interaction, selective apoptosis, tumor growth inhibition, tumor xenografts, oral anticancer drugs, cell cycle arrest
MeSH terms
Administration, Oral, Animals, Antineoplastic Agents, Cell Cycle, Humans, Indoles, Models, Molecular, Neoplasms, Protein Binding, Spiro Compounds, Time Factors, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review